• Corvus Pharmaceuticals invested $5 million in a new $13.5 million financing for China partner Angel Pharmaceuticals.
• Proceeds support Angel Pharma’s Phase 1b/2 soquelitinib trial in atopic dermatitis and a planned Phase 2 asthma study.
• Angel Pharma expects initial Phase 1b atopic dermatitis data in late 2026; asthma Phase 2 start targeted for early 2027.
• Corvus remains Angel Pharma’s largest shareholder following the investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606090730PRIMZONEFULLFEED9733767) on June 09, 2026, and is solely responsible for the information contained therein.